<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04562597</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00099062</org_study_id>
    <nct_id>NCT04562597</nct_id>
  </id_info>
  <brief_title>A Pilot Trial to Determine the Effective N-acetylcysteine Dose for Opioid Reduction for Spine Surgery.</brief_title>
  <official_title>A Pilot Trial to Determine the Effective Dose of N-acetylcysteine for Opioid Reduction in Patients Undergoing Spine Surgery.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of South Carolina</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Determine the optimal dose of IV N-acetylcysteine (NAC) to produce opioid reduction following&#xD;
      spine surgery and estimate the difference in opioid consumption between placebo and the&#xD;
      selected optimal dose.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      First 20 subjects: 5 participants will be randomized to each dose group (placebo, 50, 100,&#xD;
      and 150 mg/kg) to estimate the dose response curve and to identify the optimal dose.&#xD;
&#xD;
      If the dose response curve is adequate and the optimal dose identified, 15 additional&#xD;
      participants will be randomized to placebo and 15 to the optimal dose to estimate the&#xD;
      difference in opioid consumption between participants on placebo vs. the optimal dose. (Total&#xD;
      of 50 subjects with 20 from dose response curve and 30 to estimate the difference in opioid&#xD;
      consumption.)&#xD;
&#xD;
      If the dose response curve is not adequate after the initial 20 subjects 5 per each dose&#xD;
      group, then an additional 5 participants will be randomized and to each dose group (placebo,&#xD;
      50, 100, and 150 mg/kg) to estimate the dose response curve and to identify the optimal dose.&#xD;
      Once the optimal dose is identified with these initial 40 patients, 10 additional&#xD;
      participants will be randomized to placebo and 10 to the optimal dose to estimate the&#xD;
      difference in opioid consumption between participants on placebo vs. the optimal dose. (60&#xD;
      patients total with 40 to create the dose response curve and 20 more to estimate the&#xD;
      difference in opioid consumption.)&#xD;
&#xD;
      A sample size of 20 subjects per group (placebo and optimal dose) allows us to estimate a 95%&#xD;
      confidence interval for the mean difference in opioid consumption with a width of + 0.64&#xD;
      standard deviations from the mean. 70 subjects may be enrolled to account for withdrawal but&#xD;
      the study will be completed once 50 or 60 subjects (based on the number of subjects required&#xD;
      to create the dose response curve) have completed the protocol.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 20, 2021</start_date>
  <completion_date type="Anticipated">January 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>First 20 subjects: We will initially randomize 5 patients to each dose group (placebo, 50, 100, and 150 mg/kg) to estimate the dose response curve and to identify the optimal dose. After enrollment of the first 20 patients, the study will undergo review by the study team and statistician.&#xD;
If the dose response curve is adequate and the optimal dose identified, 15 additional participants will be randomized to placebo and 15 to the optimal dose to estimate the difference in opioid consumption between patients on placebo vs. the optimal dose.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Opioid consumption 12 hours post operative</measure>
    <time_frame>12 hours</time_frame>
    <description>Post operative opioid consumption</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Opioid consumption 6 hours post operative</measure>
    <time_frame>6 hours</time_frame>
    <description>Post operative opioid consumption</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Surgery</condition>
  <arm_group>
    <arm_group_label>Dose Response Curve Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>5-10 participants will be randomized to the placebo group to estimate the dose response curve and to identify the optimal dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Response Curve N-acetylcysteine 50 mg/kg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>5-10 participants will be randomized to the N-acetylcysteine 50 mg/kg group to estimate the dose response curve and to identify the optimal dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Response Curve N-acetylcysteine 100 mg/kg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>5-10 participants will be randomized to the N-acetylcysteine 100 mg/kg group to estimate the dose response curve and to identify the optimal dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Response Curve N-acetylcysteine 150 mg/kg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>5-10 participants will be randomized to the N-acetylcysteine 150 mg/kg group to estimate the dose response curve and to identify the optimal dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Opioid Reduction with Optimal N-acetylcysteine Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once the optimal N-acetylcysteine dose is identified, 10-15 additional participants will be randomized to the optimal dose to estimate the difference in opioid consumption between patients on placebo vs. the optimal dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>10-15 Participants will be randomized to placebo to estimate the difference in opioid consumption between patients on placebo vs. the optimal dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dose Response Curve Placebo</intervention_name>
    <description>5-10 participants will be randomized to the placebo group to estimate the dose response curve and to identify the optimal dose.</description>
    <arm_group_label>Dose Response Curve Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dose Response Curve N-acetylcysteine 50 mg/kg</intervention_name>
    <description>5-10 participants will be randomized to the N-acetylcysteine 50 mg/kg group to estimate the dose response curve and to identify the optimal dose.</description>
    <arm_group_label>Dose Response Curve N-acetylcysteine 50 mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dose Response Curve N-acetylcysteine 100 mg/kg</intervention_name>
    <description>5-10 participants will be randomized to the N-acetylcysteine 100 mg/kg group to estimate the dose response curve and to identify the optimal dose.</description>
    <arm_group_label>Dose Response Curve N-acetylcysteine 100 mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dose Response Curve N-acetylcysteine 150 mg/kg</intervention_name>
    <description>5-10 participants will be randomized to the N-acetylcysteine 150 mg/kg group to estimate the dose response curve and to identify the optimal dose.</description>
    <arm_group_label>Dose Response Curve N-acetylcysteine 150 mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Opioid Reduction with Optimal N-acetylcysteine Dose</intervention_name>
    <description>Once the optimal N-acetylcysteinedose is identified, 10-15 participants will be randomized to the optimal dose (50,100, or 150 mg/kg) to estimate the difference in opioid consumption between patients administered optimal N-acetylcysteine dose or placebo.</description>
    <arm_group_label>Opioid Reduction with Optimal N-acetylcysteine Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>10-15 Participants will be randomized to placebo to estimate the difference in opioid consumption between patients administered optimal N-acetylcysteine dose or placebo.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Undergoing elective spine surgery involving 4 levels or less of the thoracic, lumbar,&#xD;
             or sacral spine.&#xD;
&#xD;
          -  18 years of age and older.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Less than 40kg in weight.&#xD;
&#xD;
          -  Unable to provide written, informed consent.&#xD;
&#xD;
          -  History of an adverse or anaphylactoid reaction to acetylcysteine.&#xD;
&#xD;
          -  Active asthma, wheezing, or using inhaled bronchodilators.&#xD;
&#xD;
          -  Pregnant Women&#xD;
&#xD;
          -  Known blood clotting deficiency&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sylvia Wilson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sylvia Wilson, MD</last_name>
    <phone>843-792-2322</phone>
    <email>wilsosh@musc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wanda Jones, BSN</last_name>
    <phone>8437921869</phone>
    <email>joneswr@musc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvia Wilson, MD</last_name>
      <phone>843-792-2322</phone>
      <email>wilsosh@musc.edu</email>
    </contact>
    <investigator>
      <last_name>Sylvia Wilson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Hall AJ, Logan JE, Toblin RL, Kaplan JA, Kraner JC, Bixler D, Crosby AE, Paulozzi LJ. Patterns of abuse among unintentional pharmaceutical overdose fatalities. JAMA. 2008 Dec 10;300(22):2613-20. doi: 10.1001/jama.2008.802.</citation>
    <PMID>19066381</PMID>
  </reference>
  <reference>
    <citation>Pieralisi A, Martini C, Soto D, Vila MC, Calvo JC, Guerra LN. N-acetylcysteine inhibits lipid accumulation in mouse embryonic adipocytes. Redox Biol. 2016 Oct;9:39-44. doi: 10.1016/j.redox.2016.05.006. Epub 2016 May 27.</citation>
    <PMID>27281491</PMID>
  </reference>
  <reference>
    <citation>Heim MU, Alraun K, Leeping M, Schwarzfischer G, Böck M, Kling A, Mempel W. [Incidence of the detection of erythrocyte antibodies in relation to screening test cells]. Beitr Infusionsther. 1992;30:443-5. German.</citation>
    <PMID>1284756</PMID>
  </reference>
  <reference>
    <citation>Guo F, Li Y, Wang J, Li Y, Li Y, Li G. Stanniocalcin1 (STC1) Inhibits Cell Proliferation and Invasion of Cervical Cancer Cells. PLoS One. 2013;8(1):e53989. doi: 10.1371/journal.pone.0053989. Epub 2013 Jan 29.</citation>
    <PMID>23382863</PMID>
  </reference>
  <reference>
    <citation>Bavarsad Shahripour R, Harrigan MR, Alexandrov AV. N-acetylcysteine (NAC) in neurological disorders: mechanisms of action and therapeutic opportunities. Brain Behav. 2014 Mar;4(2):108-22. doi: 10.1002/brb3.208. Epub 2014 Jan 13. Review.</citation>
    <PMID>24683506</PMID>
  </reference>
  <reference>
    <citation>Tardiolo G, Bramanti P, Mazzon E. Overview on the Effects of N-Acetylcysteine in Neurodegenerative Diseases. Molecules. 2018 Dec 13;23(12). pii: E3305. doi: 10.3390/molecules23123305. Review.</citation>
    <PMID>30551603</PMID>
  </reference>
  <reference>
    <citation>Monti DA, Zabrecky G, Kremens D, Liang TW, Wintering NA, Bazzan AJ, Zhong L, Bowens BK, Chervoneva I, Intenzo C, Newberg AB. N-Acetyl Cysteine Is Associated With Dopaminergic Improvement in Parkinson's Disease. Clin Pharmacol Ther. 2019 Oct;106(4):884-890. doi: 10.1002/cpt.1548. Epub 2019 Jul 17.</citation>
    <PMID>31206613</PMID>
  </reference>
  <reference>
    <citation>Monti DA, Zabrecky G, Kremens D, Liang TW, Wintering NA, Cai J, Wei X, Bazzan AJ, Zhong L, Bowen B, Intenzo CM, Iacovitti L, Newberg AB. N-Acetyl Cysteine May Support Dopamine Neurons in Parkinson's Disease: Preliminary Clinical and Cell Line Data. PLoS One. 2016 Jun 16;11(6):e0157602. doi: 10.1371/journal.pone.0157602. eCollection 2016.</citation>
    <PMID>27309537</PMID>
  </reference>
  <reference>
    <citation>Holmay MJ, Terpstra M, Coles LD, Mishra U, Ahlskog M, Öz G, Cloyd JC, Tuite PJ. N-Acetylcysteine boosts brain and blood glutathione in Gaucher and Parkinson diseases. Clin Neuropharmacol. 2013 Jul-Aug;36(4):103-6. doi: 10.1097/WNF.0b013e31829ae713.</citation>
    <PMID>23860343</PMID>
  </reference>
  <reference>
    <citation>Coles LD, Tuite PJ, Öz G, Mishra UR, Kartha RV, Sullivan KM, Cloyd JC, Terpstra M. Repeated-Dose Oral N-Acetylcysteine in Parkinson's Disease: Pharmacokinetics and Effect on Brain Glutathione and Oxidative Stress. J Clin Pharmacol. 2018 Feb;58(2):158-167. doi: 10.1002/jcph.1008. Epub 2017 Sep 22.</citation>
    <PMID>28940353</PMID>
  </reference>
  <reference>
    <citation>Halboub E, Alkadasi B, Alakhali M, AlKhairat A, Mdabesh H, Alkahsah S, Abdulrab S. N-acetylcysteine versus chlorhexidine in treatment of aphthous ulcers: a preliminary clinical trial. J Dermatolog Treat. 2021 Sep;32(6):649-653. doi: 10.1080/09546634.2019.1688231. Epub 2019 Nov 21.</citation>
    <PMID>31679408</PMID>
  </reference>
  <reference>
    <citation>Li J, Xu L, Deng X, Jiang C, Pan C, Chen L, Han Y, Dai W, Hu L, Zhang G, Cheng Z, Liu W. N-acetyl-cysteine attenuates neuropathic pain by suppressing matrix metalloproteinases. Pain. 2016 Aug;157(8):1711-1723. doi: 10.1097/j.pain.0000000000000575.</citation>
    <PMID>27075430</PMID>
  </reference>
  <reference>
    <citation>Notartomaso S, Scarselli P, Mascio G, Liberatore F, Mazzon E, Mammana S, Gugliandolo A, Cruccu G, Bruno V, Nicoletti F, Battaglia G. N-Acetylcysteine causes analgesia in a mouse model of painful diabetic neuropathy. Mol Pain. 2020 Jan-Dec;16:1744806920904292. doi: 10.1177/1744806920904292.</citation>
    <PMID>32009537</PMID>
  </reference>
  <reference>
    <citation>Dludla PV, Nkambule BB, Dias SC, Johnson R. Cardioprotective potential of N-acetyl cysteine against hyperglycaemia-induced oxidative damage: a protocol for a systematic review. Syst Rev. 2017 May 12;6(1):96. doi: 10.1186/s13643-017-0493-8.</citation>
    <PMID>28499416</PMID>
  </reference>
  <reference>
    <citation>Hoffer BJ, Pick CG, Hoffer ME, Becker RE, Chiang YH, Greig NH. Repositioning drugs for traumatic brain injury - N-acetyl cysteine and Phenserine. J Biomed Sci. 2017 Sep 9;24(1):71. doi: 10.1186/s12929-017-0377-1. Review.</citation>
    <PMID>28886718</PMID>
  </reference>
  <reference>
    <citation>Howard RJ, Blake DR, Pall H, Williams A, Green ID. Allopurinol/N-acetylcysteine for carbon monoxide poisoning. Lancet. 1987 Sep 12;2(8559):628-9.</citation>
    <PMID>2887913</PMID>
  </reference>
  <reference>
    <citation>Hamamsy ME, Bondok R, Shaheen S, Eladly GH. Safety and efficacy of adding intravenous N-acetylcysteine to parenteral L-alanyl-L-glutamine in hospitalized patients undergoing surgery of the colon: a randomized controlled trial. Ann Saudi Med. 2019 Jul-Aug;39(4):251-257. doi: 10.5144/0256-4947.2019.251. Epub 2019 Aug 5.</citation>
    <PMID>31381364</PMID>
  </reference>
  <reference>
    <citation>Soleimani A, Habibi MR, Hasanzadeh Kiabi F, Alipour A, Habibi V, Azizi S, Emami Zeydi A, Sohrabi FB. The effect of intravenous N-acetylcysteine on prevention of atrial fibrillation after coronary artery bypass graft surgery: a double-blind, randomised, placebo-controlled trial. Kardiol Pol. 2018;76(1):99-106. doi: 10.5603/KP.a2017.0183. Epub 2017 Oct 5.</citation>
    <PMID>28980294</PMID>
  </reference>
  <reference>
    <citation>Sins JWR, Fijnvandraat K, Rijneveld AW, Boom MB, Kerkhoffs JH, van Meurs AH, de Groot MR, Heijboer H, Dresse MF, Lê PQ, Hermans P, Vanderfaeillie A, Van Den Neste EW, Benghiat FS, Kesse-Adu R, Delannoy A, Efira A, Azerad MA, de Borgie CA, Biemond BJ. Effect of N-acetylcysteine on pain in daily life in patients with sickle cell disease: a randomised clinical trial. Br J Haematol. 2018 Aug;182(3):444-448. doi: 10.1111/bjh.14809. Epub 2017 Jun 23.</citation>
    <PMID>28643376</PMID>
  </reference>
  <reference>
    <citation>Heidari N, Sajedi F, Mohammadi Y, Mirjalili M, Mehrpooya M. Ameliorative Effects Of N-Acetylcysteine As Adjunct Therapy On Symptoms Of Painful Diabetic Neuropathy. J Pain Res. 2019 Nov 19;12:3147-3159. doi: 10.2147/JPR.S228255. eCollection 2019.</citation>
    <PMID>31819599</PMID>
  </reference>
  <reference>
    <citation>Kerr F, Dawson A, Whyte IM, Buckley N, Murray L, Graudins A, Chan B, Trudinger B. The Australasian Clinical Toxicology Investigators Collaboration randomized trial of different loading infusion rates of N-acetylcysteine. Ann Emerg Med. 2005 Apr;45(4):402-8.</citation>
    <PMID>15795719</PMID>
  </reference>
  <reference>
    <citation>Yip L, Dart RC. A 20-hour treatment for acute acetaminophen overdose. N Engl J Med. 2003 Jun 12;348(24):2471-2.</citation>
    <PMID>12802041</PMID>
  </reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>September 10, 2020</study_first_submitted>
  <study_first_submitted_qc>September 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 24, 2020</study_first_posted>
  <last_update_submitted>February 12, 2021</last_update_submitted>
  <last_update_submitted_qc>February 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of South Carolina</investigator_affiliation>
    <investigator_full_name>Sylvia Wilson</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

